Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Gene expression profiling predicts clinical outcome of breast cancer

van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536

Multidrug resistance in cancer: role of ATP–dependent transporters

Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356

Cancer incidence, mortality and prevalence worldwide

Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081

Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line

Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925

The National Comprehensive Cancer Network (NCCN).

Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765

A multidrug resistance transporter from human MCF-7 breast cancer cells

Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells

Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858

A family of drug transporters: the multidrug resistance-associated proteins

Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751

Molecular mechanisms of drug resistance

Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,317

Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein

Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867

The Role of ABC Transporters in Clinical Practice

Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817

Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.

Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., & Deeley, R. G. (1994) · PubMed · Cited by 770

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736

Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer

Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685

Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization

Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681

Drug Resistance and ATP-Dependent Conjugate Transport Mediated by the Apical Multidrug Resistance Protein, MRP2, Permanently Expressed in Human and Canine Cells

Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676

Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in Human Breast Cancer

Hwang, D., Byrne, J., Scollard, D., & Levine, E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.455 · Cited by 651

MRP3, an organic anion transporter able to transport anti-cancer drugs

Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M. L., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., Scheper, R. J., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6914 · Cited by 645

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.

Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607

Expression of survivin and its relationship to loss of apoptosis in breast carcinomas

田中, 慶. (2000) · Medical Entomology and Zoology · doi:10.11501/3179364 · Cited by 559

DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis

Bernstein, C. (2002) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(02)00009-1 · Cited by 527

Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies

Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521

Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)

Kowalski, R. J., Giannakakou, P., & Hamel, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2534 · Cited by 511

Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

Fan, S., Smith, M. L., Rivet, D. J., Duba, D. E., Zhan, Q., Kohn, K. W., Fornace, A. J., & O'Connor, P. M. (1995) · PubMed · Cited by 490

A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., & Fojo, T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040546297 · Cited by 477

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453

Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., & Jansen, G. (1999) · PubMed · Cited by 442

Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance

Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434

Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Pérez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M. C., & Bates, S. E. (2001) · PubMed · Cited by 429

Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer

Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413

Autophagy: a barrier or an adaptive response to cancer

Ogier-Denis, E., & Codogno, P. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00004-0 · Cited by 365

Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)

Hirohashi, T., Suzuki, H., & Sugiyama, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15181 · Cited by 347

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326

Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling

Iwao-Koizumi, K., Matoba, R., Ueno, N., Kim, S. J., Ando, A., Miyoshi, Y., Maeda, E., Noguchi, S., & Kato, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.078 · Cited by 309

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

Fumoleau, P., Largillier, R., Clippe, C., Dièras, V., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 305

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302

Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.

Mechetner, E. B., Kyshtoobayeva, A. S., Zonis, S., Kim, H. J., Stroup, R., Garcia, R., Parker, R. J., & Fruehauf, J. P. (1998) · PubMed · Cited by 291

Standard of care.

Berlin, L. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.2.9456928 · Cited by 272

ATP binding cassette transporters and drug resistance in breast cancer.

Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251

βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability

Kamath, K., Wilson, L., Cabral, F., & Jordan, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414477200 · Cited by 247

The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays

Smith, L., Watson, M. B., O'Kane, S. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0190 · Cited by 235

Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens

Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T., & Sugimoto, Y. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.610 · Cited by 235

Fas expression and function in normal and malignant breast cell lines.

Keane, M., Ettenberg, S. A., Lowrey, G. A., RUSSELL, E. K., & Lipkowitz, S. (1996) · PubMed · Cited by 231

False-negative results in screening programmes: systematic review of impact and implications.

Petticrew, Sowden, Lister-Sharp, & Wright (2000) · Health Technology Assessment · doi:10.3310/hta4050 · Cited by 225

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

Kavallaris, M., Tait, A., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., & Haber, M. (2001) · PubMed · Cited by 221

p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

Sáez, R., Molina, M. A., Ramsey, E. E., Rojo, F., Keenan, E. J., Albanell, J., Lluch, A., García-Conde, J., Baselga, J., & Clinton, G. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1807 · Cited by 218

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Low, J. A., Wedam, S. B., Lee, J. J., Berman, A. W., Brufsky, A., Yang, S. X., Poruchynsky, M. S., Steinberg, S. M., Mannan, N., Fojo, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.024 · Cited by 215

Inhibition of P-Glycoprotein Function and Expression by Kaempferol and Quercetin

Limtrakul, P., Khantamat, O., & Pintha, K. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.1.86 · Cited by 210

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., & Baselga, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1923 · Cited by 198

Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma

König, J., Hartel, M., Nies, A. T., Martignoni, M. E., Guo, J., Büchler, M. W., Friess, H., & Keppler, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20831 · Cited by 194

The Biology and Medicinal Chemistry of Epothilones

Wartmann, M., & Altmann, K. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354489 · Cited by 182

Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol

Kavallaris, M., Burkhart, C. A., & Horwitz, S. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690507 · Cited by 179

The Mechanism of Action of Multidrug-Resistance-Linked P-Glycoprotein

Sauna, Z. E., Smith, M. M., Müller, M., Kerr, K. M., & Ambudkar, S. V. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012875105006 · Cited by 178

Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents.

Zeng, H., Bain, L. J., Belinsky, M. G., & Kruh, G. D. (1999) · PubMed · Cited by 173

MRP Subfamily Transporters and Resistance to Anticancer Agents

Kruh, G. D., Zeng, H., Rea, P. A., Liu, G., Chen, Z.-S., Lee, K., & Belinsky, M. G. (2001) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1012827221844 · Cited by 170

Estrogen-Mediated Post transcriptional Down-regulation of Breast Cancer Resistance Protein/ABCG2

Imai, Y., Ishikawa, E., Asada, S., & Sugimoto, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.596.65.2 · Cited by 169

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients

Del Vecchio, S., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., Thomas, R., Cerra, M., D'Aiuto, G., Tsuruo, T., et al. (1997) · European Journal of Nuclear Medicine · doi:10.1007/bf02439547 · Cited by 163

The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells

Zhang, C. C., Yang, J.-M., White, E., Murphy, M., Levine, A., & Hait, W. N. (1998) · Oncogene · doi:10.1038/sj.onc.1201658 · Cited by 159

Do β-tubulin mutations have a role in resistance to chemotherapy?

Berrieman, H. K., Lind, M., & Cawkwell, L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01411-1 · Cited by 153

Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers

Xia, W., Husain, I., Liu, L.-H., Bacus, S. S., Saini, S., Spohn, J., Pry, K. J., Westlund, R. E., Stein, S. H., & Spector, N. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2101 · Cited by 148

Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer

Degardin, M., Bonneterre, J. M., Hecquet, B., Pion, J. M., Adeins, A., Horner, D., & Demaille, A. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058873 · Cited by 142

Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines.

He, L., Yang, C. P., & Horwitz, S. B. (2001) · PubMed · Cited by 131

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

Cleator, S. J., Tsimelzon, A. I., Ashworth, A., Dowsett, M., Dexter, T., Powles, T. J., Hilsenbeck, S. G., Wong, H. H., Osborne, C. K., O'Connell, P., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9009-7 · Cited by 129

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Brooks, T. A., Minderman, H., O’Loughlin, K. L., Pera, P. J., Ojima, I., Baer, M. R., Bernacki, R. J., & Brooks, T. A. (2003) · PubMed · Cited by 119

Resistance to topoisomerase poisons due to loss of DNA mismatch repair

Fedier, A., Schwarz, V. A., Walt, H., Carpini, R. D., Haller, U., & Fink, D. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1356 · Cited by 117

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

Bianchi, G., Loibl, S., Zamagni, C., Salvagni, S., Raab, G., Siena, S., Laferriere, N., Peña, C. E., Lathia, C. D., Bergamini, L., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b2ea0 · Cited by 116

Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.

Hasegawa, S., Miyoshi, Y., Egawa, C., Ishitobi, M., Taguchi, T., Tamaki, Y., Monden, M., & Noguchi, S. (2003) · PubMed · Cited by 113

Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., & Giaccone, G. (1997) · International Journal of Cancer · Cited by 112

Pseudolaric Acid B, a Novel Microtubule-Destabilizing Agent That Circumvents Multidrug Resistance Phenotype and Exhibits Antitumor Activity In vivo

Wong, V. K. W., Chiu, P., Chung, S. S. M., Chow, L. M. C., Zhao, Y., Yang, B. B., & Ko, B. C. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0209 · Cited by 112

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.

Lister-Sharp, D., McDonagh, M. S., Khan, K. S., & Kleijnen, J. (2000) · Health Technology Assessment · doi:10.3310/hta4170 · Cited by 109

Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study

Solary, É., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.-Y. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1198.bloodjournal8841198 · Cited by 109

Microtubule Alterations and Mutations Induced by Desoxyepothilone B

Verrills, N. M., Flemming, C. L., Liu, M., Ivery, M. T. G., Cobon, G. S., Norris, M. D., Haber, M., & Kavallaris, M. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(03)00141-8 · Cited by 108

Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.

Sládek, N. E. (1999) · PubMed · Cited by 107

Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group

Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.033 · Cited by 105

Aldehyde Dehydrogenase-Mediated Cellular Relative Insensitivity to the Oxazaphosphorines1

Sládek, N. E. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230110215319 · Cited by 105

Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization

Lou, P., Lai, P., Shieh, M., MacRobert, A. J., Berg, K., & Bown, S. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.22098 · Cited by 100

Inhibition of Multidrug Resistance of Cancer Cells by Natural Diterpenes, Triterpenes and Carotenoids

Molnar, J. A., Gyémánt, N., Tanaka, M., Hohmann, J., Bergmann‐Leitner, E. S., Molnár, P., Deli, J., Didiziapetris, R., & Ferreira, M. U. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201893 · Cited by 99

Cell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen

Scudiero, D. A., Monks, A. P., & Sausville, E. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.862 · Cited by 96

Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence

Barnes, N. L. P., Haywood, P., Flint, P., Knox, W. F., & Bundred, N. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602932 · Cited by 88

Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer

Saeki, T., Nomizu, T., Toi, M., Ito, Y., Noguchi, S., Kobayashi, T., Asaga, T., Minami, H., Yamamoto, N., Aogi, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1646 · Cited by 84

Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy

Rudas, M., Filipits, M., Taucher, S., Stranzl, T., Steger, G. G., Jakesz, R., Pirker, R., & Pohl, G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025751631115 · Cited by 82

Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

Surowiak, P., Materna, V., Matkowski, R., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1313 · Cited by 81

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies

Fracasso, P. M., Westerveldt, P., Fears, C. L., Rosen, D. M., Zuhowski, E. G., Cazenave, L. A., Litchman, M., & Egorin, M. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1124 · Cited by 80

Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road

Lothstein, L., Israel, M., & Sweatman, T. W. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0201 · Cited by 76

Overexpression of Caspase-3s Splice Variant in Locally Advanced Breast Carcinoma Is Associated with Poor Response to Neoadjuvant Chemotherapy

Végran, F., Boidot, R., Oudin, C., Riedinger, J., Bonnetain, F., & Lizard‐Nacol, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0725 · Cited by 76

Dissociation of Bax from a Bcl-2/Bax Heterodimer Triggered by Phosphorylation of Serine 70 of Bcl-2

Shitashige, M., Toi, M., Yano, T., Shibata, M. S., Matsuo, Y., & Shibasaki, F. (2001) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a003044 · Cited by 74

TP53 mutations in familial breast cancer: Functional aspects

Gasco, M., Yuluğ, I. G., & Crook, T. (2003) · Human Mutation · doi:10.1002/humu.10173 · Cited by 71

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

Soto, J. A. D., & Deng, C. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.117 · Cited by 71

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel

Withoff, S., Keith, W. N., Knol, A., Coutts, J., Hoare, S. F., Mulder, N., & de Vries, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.393 · Cited by 69

Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.

Brown, G., McPherson, J. P., Gu, L., Hedley, D. W., Toso, R., Deuchars, K. L., Freedman, M. H., & Goldenberg, G. J. (1995) · PubMed · Cited by 55

Differential expression of DNA topoisomerase II α and -β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4

Withoff, S., de Vries, E., Keith, W. N., Nienhuis, E., van der Graaf, W., Uges, D., & Mulder, N. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.647 · Cited by 53

Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).

Burris, H. A. (2000) · PubMed · Cited by 50

p53 expression and resistance against paclitaxel in patients with metastatic breast cancer

Schmidt, M., Bachhuber, A., Victor, A., Steiner, E., Mahlke, M., Lehr, H., Pilch, H., Weikel, W., & Knapstein, P. G. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0430-1 · Cited by 46

Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results

Sun, S., Hsieh, J., Tsai, S., Ho, Y., Lee, J.-K., & Kao, C. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00356-6 · Cited by 44

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).

Withoff, S., de Jong, S., de Vries, E. G. E., et al. (1996) · PubMed · Cited by 43

Breast cancer (metastatic).

Stebbing, J., Crane, J., & Gaya, A. (2002) · Europe PMC (PubMed Central) · Cited by 38

Paclitaxel resistance in cells with reduced β-tubulin

Wang, Y., & Cabral, F. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.12.003 · Cited by 37

Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis

Driouch, K., Landemaine, T., Sin, S., Wang, S., & Lidereau, R. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9110-x · Cited by 29

Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer

Barton, M. C., Akli, S., & Keyomarsi, K. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20818 · Cited by 28

Successful targeting of ErbB2 receptors—is PTEN the key?

Crowder, R. J., Lombardi, D. P., & Ellis, M. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.001 · Cited by 24

Combination chemotherapy for metastatic breast cancer

Nabholtz, J.-M. A., Reese, D., Lindsay, M.-A., & Riva, A. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.2.169 · Cited by 24

Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report

Conte, P., Thomas, E., Martin, M. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10505 · Cited by 16

Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665

Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer

Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511

A Review of Clinical Translation of Inorganic Nanoparticles

Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509

The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing

Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

Chang, A. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.022 · Cited by 443